Search Results - "PARHAM, Laura R"
-
1
Prospective Validation of HLA-DRB107:01 Allele Carriage As a Predictive Risk Factor for Lapatinib-Induced Liver Injury
Published in Journal of clinical oncology (01-08-2014)“…Liver injury is a serious adverse event leading to permanent discontinuation of lapatinib in affected patients. This study aimed to validate previously…”
Get full text
Journal Article -
2
Pharmacogenetic investigation of efficacy response to mepolizumab in eosinophilic granulomatosis with polyangiitis
Published in Rheumatology international (01-08-2020)“…Treatment of patients with the rare disease eosinophilic granulomatosis with polyangiitis (EGPA) with mepolizumab, a monoclonal antibody to interleukin-5…”
Get full text
Journal Article -
3
Rash in lapatinib-treated patients is not associated with human leukocyte antigen polymorphisms
Published in Pharmacogenomics (01-07-2015)“…Rash is a common side effect of lapatinib treatment. Since human leukocyte antigen ( ) alleles have been implicated in multiple drug-induced cutaneous…”
Get full text
Journal Article -
4
Prospective Validation of HLA-DRB1 07:01 Allele Carriage As a Predictive Risk Factor for Lapatinib-Induced Liver Injury
Published in Journal of clinical oncology (01-08-2014)Get full text
Journal Article -
5
VEGF polymorphism may be associated with overall survival in lapatinib-treated breast cancer patients with brain metastases
Published in Journal of clinical oncology (20-05-2012)“…Abstract only 10532 Background: Lapatinib is a dual HER2/EGFR tyrosine kinase inhibitor (TKI) approved in combination with capecitabine or letrozole for…”
Get full text
Journal Article